A Study to Evaluate the Efficacy of Propranolol in Boosting Immunotherapy in Hepatocellular Carcinoma, Cholangiocarcinoma and Pancreatic Adenocarcinoma
Latest Information Update: 14 Jun 2024
At a glance
- Drugs Cisplatin (Primary) ; Durvalumab (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary) ; Propranolol (Primary) ; Tremelimumab (Primary)
- Indications Adenocarcinoma; Cholangiocarcinoma; Liver cancer; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms BLOCKED
Most Recent Events
- 11 Jun 2024 Status changed from not yet recruiting to recruiting.
- 01 Feb 2023 Planned initiation date changed from 1 Oct 2022 to 1 Mar 2023.
- 14 Jul 2022 New trial record